HK1184055A1 - Use of botulinum toxin for treating hyperhydrosis - Google Patents

Use of botulinum toxin for treating hyperhydrosis

Info

Publication number
HK1184055A1
HK1184055A1 HK13111511.2A HK13111511A HK1184055A1 HK 1184055 A1 HK1184055 A1 HK 1184055A1 HK 13111511 A HK13111511 A HK 13111511A HK 1184055 A1 HK1184055 A1 HK 1184055A1
Authority
HK
Hong Kong
Prior art keywords
botulinum toxin
treating hyperhydrosis
hyperhydrosis
treating
botulinum
Prior art date
Application number
HK13111511.2A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew M Blumenfeld
Franklin David Gaylis
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1184055A1 publication Critical patent/HK1184055A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK13111511.2A 2007-02-15 2013-10-11 Use of botulinum toxin for treating hyperhydrosis HK1184055A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89005207P 2007-02-15 2007-02-15

Publications (1)

Publication Number Publication Date
HK1184055A1 true HK1184055A1 (en) 2014-01-17

Family

ID=39689504

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111511.2A HK1184055A1 (en) 2007-02-15 2013-10-11 Use of botulinum toxin for treating hyperhydrosis

Country Status (7)

Country Link
US (4) US8383103B2 (xx)
EP (2) EP2583687B1 (xx)
JP (1) JP2010519211A (xx)
CA (1) CA2678038C (xx)
ES (2) ES2441961T3 (xx)
HK (1) HK1184055A1 (xx)
WO (1) WO2008101098A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2420430T3 (es) 2005-03-03 2013-08-23 Allergan, Inc. Sistema libre de productos de origen animal y procedimiento de purificación de una toxina botulínica
ES2441961T3 (es) 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
US8273721B2 (en) * 2008-03-05 2012-09-25 Endo Pharmaceuticals Solutions Inc. Combination treatment for bladder cancer
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
US20120294844A1 (en) * 2011-01-07 2012-11-22 Revance Therapeutics, Inc. Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
WO2012174123A1 (en) * 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
EP2731590B1 (en) * 2011-07-13 2018-05-23 The Foundry, LLC Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
CN106714824A (zh) 2014-07-16 2017-05-24 纽约大学 透明质酸酶用于治疗肌肉僵硬的用途
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
BR112017016759B1 (pt) 2015-02-03 2021-01-12 Merz Pharma Gmbh & Co. Kgaa seringa de plástico pré-carregada, kit, uso da seringa de plástico pré-carregada e método para o tratamento cosmético da pele
RU2605624C1 (ru) * 2015-11-23 2016-12-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Способ лечения детрузорной гиперактивности
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054190B2 (ja) 1989-01-27 2000-06-19 イムノリティックス・インコーポレイテッド 良性前立腺肥大処置のための組成物および方法
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
CA2210248A1 (en) * 1995-01-13 1996-07-18 Ronald M. Evans Allosteric control of nuclear hormone receptors
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
PT1011695E (pt) 1997-07-15 2006-07-31 Univ Colorado Utilizacao de terapia com neurotoxina para tratamento de doencas da prostata
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6428785B1 (en) * 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2001296915A1 (en) 2000-09-26 2002-04-08 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
BR0006556A (pt) * 2000-12-28 2002-09-17 Apsen Farmaceutica S A Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US20040067235A1 (en) 2002-07-29 2004-04-08 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2460881B1 (en) * 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of CNS
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
CA2948238A1 (en) * 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20090324647A1 (en) * 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
KR101235135B1 (ko) * 2005-12-19 2013-02-20 삼성디스플레이 주식회사 금속 배선, 이의 제조 방법, 이를 구비한 표시 기판 및표시 기판의 제조 방법
US20090304747A1 (en) 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
ES2441961T3 (es) 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos

Also Published As

Publication number Publication date
US8697066B2 (en) 2014-04-15
US8383103B2 (en) 2013-02-26
EP2117584B1 (en) 2013-10-09
ES2441961T3 (es) 2014-02-07
CA2678038C (en) 2016-10-11
WO2008101098A2 (en) 2008-08-21
JP2010519211A (ja) 2010-06-03
US20080199452A1 (en) 2008-08-21
ES2520765T3 (es) 2014-11-11
EP2117584A2 (en) 2009-11-18
US20130129699A1 (en) 2013-05-23
EP2583687A1 (en) 2013-04-24
WO2008101098A3 (en) 2008-10-16
US8388952B2 (en) 2013-03-05
CA2678038A1 (en) 2008-08-21
US20130142770A1 (en) 2013-06-06
EP2583687B1 (en) 2014-08-27
US20080199453A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
HK1184055A1 (en) Use of botulinum toxin for treating hyperhydrosis
IL195201A0 (en) High frequency application of botulinum toxin therapy
EP2300005A4 (en) Small-molecule inhibitors of botulinum neurotoxins
EP2337778A4 (en) METHODS OF TREATING BOTULINUM TOXIN-RELATED DISEASE IN A SUBJECT
IL205280A0 (en) Methods of treating chronic neurogenic inflammation using modified clostridial toxins
EP2338519A4 (en) MEANS FOR THE TREATMENT OF MYELOFIBROSIS
IL199907A0 (en) Composition for treatment of pancreatic cancer
EP2490530A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
PT2310034E (pt) Péptidos para o tratamento de beta-amiloidoses
EP2419128A4 (en) MANIPULATED BOTULINUM NEUROTOXIN
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IL193639A0 (en) Collagenase for treating cellulite
EP2313434A4 (en) NEUTRALIZING ANTIBODIES OF BOTULINIC NEUROTOXINS
IL207292A0 (en) Use of ranolazine for treating pain
IL214665A (en) Alkyl-amido compounds and their uses in the treatment of acne
HK1163524A1 (zh) 胰腺腫瘤治療
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
EP2368559A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF ATHEROSCLEROSIS
EP2397460A4 (en) NITROGEN-CONTAINING COMPOUNDS AND AGENTS FOR CONTROLLING HARMFUL ORGANISMS
HK1174532A1 (en) Compositions comprising botulinum toxin a or b for use in the treatment of osteoporosis a b
ZA200807221B (en) Collagenase for treating cellulite
EP2510931A4 (en) THERAPEUTIC AGENT FOR THE PREVENTION AND TREATMENT OF ADENOMA AND PROSTATITIS
EP2484385A4 (en) COMPOSITION FOR THE TREATMENT OF PANCREATIC CANCER

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220217